相关实验视频

Updated: May 5, 2026

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

16.3K

校正:elexacaftor-tezacaftor-ivacaftor对Phe508del大鼠鼻电位差异和肺功能的影响

Nicole Reyne1,2,3, Patricia Cmielewski1,2,3, Alexandra McCarron1,2,3

  • 1Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.

Frontiers in pharmacology
|June 12, 2024
PubMed
概括

这项研究纠正了上一篇文章DOI. 修正的文章DOI是10.3389/fphar.2024.1362325,确保科学信息的准确引用和检索.

关键词:
在CFTR调制器.在X射线速度测试中,X射线速度测量囊性纤维化症是什么肺功能 肺功能 肺功能鼻腔潜能差异的不同模拟老鼠模型的老鼠模型

更多相关视频

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

7.7K
Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

2.8K

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97